Loading
Traws Pharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ORBIMED ADVISORS LLC, was filed 28 Apr 2026.
Traws Pharma, Inc.: what insiders have been doing
Every trade that managers of Traws Pharma, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 23 October 2026, brought 11 filings signed by 11 insiders.
Only purchases show up on the open market, 1 purchase in all worth €847k, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder. At €847k, the purchase published on 28 April 2026 by Orbimed Advisors LLC is the largest of the period (12.0% of market cap).
The last purchase on record was published on 28 April 2026, which is 179 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 11 filings, this issuer sits below that mark. Since 2016, the database holds 48 purchases and 26 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 9.2 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
139
Thresholds
n/a
Buy Volume
€10M
48 ops. · all time
Sell Volume
€1M
26 ops. · all time
Who traded when
BuySaleOrbimed Advisors LLC1 buy
Since the insiders bought
- -60.8%Entry US$1.30 · Close at T+90 US$0.51
- -29.4%Entry US$50.25 · Close at T+365 US$35.50
- -77.0%Entry US$95.75 · Close at T+365 US$22.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.37
Analyst consensus
1 analysts3.00/5
US$1.00Target US$1.00(+174%)US$1.00
Income statement
RevenueUS$2.8M
EBITDA-US$17.8M-638% margin
Net incomeUS$9.2M328.7% margin
Valuation
PER (forward)-0.2x
P/Book3.3x
Beta1.53
Balance sheet & cash
Market capUS$5.6M
Free Cash Flow-US$20.8M
Profitability & ownership
ROE-433.4%
ROA-99.4%
% insiders5.4%
% institutions40.1%
Last declaration on 28 April 2026
Declarations139 total
597,729 shares@ US$1.6712.04% mcap100.0% of flowCommon StockSEC:0000947871-26-000481:0
Canonical exit: 15 Jul 2026 (T+90)
15,393 shares0Common StockSEC:0002125562-26-000004:0
16,419 shares0Common StockSEC:0002018274-25-000004:0
18,471 shares0Common StockSEC:0002018150-25-000004:0
16,419 shares0Common StockSEC:0002017800-25-000004:0
6,157 shares0Common StockSEC:0001958857-25-000007:0
6,157 shares0Common StockSEC:0001813552-25-000005:0
4,058 shares0Common StockSEC:0001586657-25-000008:0
4,874 shares0Common StockSEC:0001237419-25-000004:0
6,157 shares0Common StockSEC:0001203603-25-000006:0
36,943 shares0Common StockSEC:0001681955-25-000004:0
605,531 sharesCommon StockSEC:0001104659-25-033149:0
96,348 shares@ US$0.01100.0% of flowCommon StockSEC:0001415889-25-004727:0
67,500 sharesCommon StockSEC:0000929638-24-002743:0
67,500 sharesCommon StockSEC:0000929638-24-002742:0
2,221 shares@ US$0.471.4% of flowCommon StockSEC:0001415889-24-017636:1
5,500 sharesCommon StockSEC:0001415889-24-017636:0
67,550 sharesCommon StockSEC:0000929638-24-001358:1
1,645,100 sharesCommon StockSEC:0000929638-24-001358:2
67,550 sharesCommon StockSEC:0000929638-24-001360:1
885,532 sharesCommon StockSEC:0000929638-24-001360:2
1,645,100 sharesCommon StockSEC:0000929638-24-001360:3
97,500 sharesCommon StockSEC:0000929638-24-001364:0
97,500 sharesCommon StockSEC:0000929638-24-001366:0
66,687 sharesCommon StockSEC:0000929638-24-001360:0
25 of 139 declarations
About Traws Pharma, Inc.
Traws Pharma, Inc. is a pharmaceutical company listed on the XNAS market. It focuses on developing innovative treatments for various diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
